Lorlatinib es un tratamiento dominante frente a alectinib y coste-efectivo frente...
Leer [+]
Healthcare Evaluation

Healthcare Evaluation
BROCHURES

Healthcare Evaluation
BROCHURES
Lorlatinib es un tratamiento dominante frente a alectinib y coste-efectivo frente...
Leer [+]Miguel Ángel Casado, director general de Pharmacoeconomics & Outcomes Research Iberia...
Leer [+]Lorlatinib es un tratamiento dominante frente a alectinib y coste-efectivo frente...
Leer [+]Miguel Ángel Casado, director general de Pharmacoeconomics & Outcomes Research Iberia...
Leer [+]PORIB seeks to demonstrate the efficiency of health interventions, based on their costs and health outcomes.
PORIB aims to achieve the value-based pricing of drugs and medical devices and its public financing.
PORIB promotes communication and negotiation strategies to favour patient access to health interventions.
PORIB studies and analyses the effectiveness of health interventions to complement its efficacy and safety data.
PORIB carries out studies that shown clinical, economic, humanistic, and social evidence of health interventions.
PORIB develops projects for placing the patient at the centre and improving the sustainability of the systems.
PORIB organises meetings with stakeholders to share knowledge with the objective of favouring patient access.
PORIB synthesise the information and objective understanding of health and socio-economic outcomes